Laboratory information management system GoMeyra LIMS reported on Thursday the launch of the revolutionary new tech solution that triples daily testing capacity and provides test results within hours for medical laboratories and practices.
A Silicon Valley visionary and experienced systems IT developer created GoMeyra during the COVID-19 lockdown to address the testing crisis created by the pandemic, which exposed the drawbacks of antiquated systems and workforce shortages at labs across the country.
According to the company, its cloud-based solution enables unprecedented COVID-19 processing times for PCR, rapid antigen and antibody testing, as well as vaccine monitoring. It serves as the end-to-end processing platform for US labs, medical providers, contractors, corporations, universities, casinos, live entertainment productions and professional sporting events to handle large-scale testing, help control the coronavirus outbreak as well as get more Americans back to work, school, travel and normal activities.
The medical practice clients powered by GoMeyra LIMS include University of South Carolina in Columbia, SC, handling on-campus rapid testing; COVID Testing LLC in Orlando, managing student testing for the University of Central Florida; American Molecular Laboratories in Chicago; Millenia Advanced Scientific in Orlando, Vital Medical Diagnostics Inc in Houston; and Vitae Diagnostics in Southern California.
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine